A Phase 2 interventional study of Entospletinib and Idelalisib in Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma, sponsored by Gilead Sciences. Terminated at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-02.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 1 under way, none of them phase 3. idelalisib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 14th largest by enrollment, is one of 3 that started in 2013, is one of 11 in phase 2, and was the 13th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →1 of the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Australia, Austria and 14 more countries
Ages 18+
By country, each count listing its studies:
idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 8 · Phase 4 1
First in 2008; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 102 across the 25 interventional studies. Of the 22 that completed or were terminated, 21 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 25 have an industry lead sponsor. The 7 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
36 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gilead Sciences: none open now, none under way, none of them phase 3. Of 32 finished, 22 (69%) have results posted.
Among the 36 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gilead Sciences, this one is the 16th largest by enrollment of the 35 interventional ones that give a count, is one of 7 that started in 2013, is one of 9 in phase 2, and was the 24th registered.
Gilead Sciences’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 36 in Leukemia, Lymphocytic, Chronic, B-Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy of the combination entospletinib and idelalisib in participants with relapsed or refractory hematologic malignancies. Participants will be enrolled who have one of the following hematological tumor types: chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), or indolent non-Hodgkin lymphomas (iNHL; including follicular lymphoma (FL) and lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia [LPL/WM], small lymphocytic lymphoma [SLL], or marginal zone lymphoma [MZL]).
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Entospletinib plus idelalisib at one of 4 dose combinations (400 mg/100 mg; 600 mg/100 mg; 800 mg/100 mg; 800 mg/150 mg). After discontinuation of entospletinib+idelalisib combination therapy, and following a washout period, participants may continue to receive entospletinib 400 mg monotherapy.
Drug: Entospletinib · Drug: Idelalisib
Entospletinib tablets administered orally twice daily
Also known as: GS-9973
Idelalisib tablets administered orally twice daily
Also known as: GS-1101, GS 1101, Cal-101, Cal 101, Zydelig®
Objective Response Rate (ORR)
ORR assessed by the Independent Review Committee (IRC), was based on the International Working Group Revised Response Criteria (Cheson, 2012) and investigator's response, defined as the percentage of participants achieving a complete response (CR) or partial response (PR) (or very good partial response \[VGPR\] or minor response \[MR\] for participants with LPL/WM). CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined as a ≥ 50% reduction in the sum of the products of the longest perpendicular diameters of all index lesions, with no new lesions. VGPR and MR were defined as ≥ 90% and ≥ 25% but \< 50% decrease from baseline in serum monoclonal immunoglobulin M (IgM) concentration by serum protein electrophoresis (SPEP) respectively.
Time frame: Start of treatment to end of treatment (Up to 18 months)
Percentage of Participants Experiencing Treatment-Emergent Adverse Events
A treatment-emergent Adverse Event (AE) was defined as any AE with an onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drugs or an AE leading to premature discontinuation of study drug. An AE is any untoward medical occurrence in a clinical investigation where participants administered a medicinal product, and which does not necessarily have a causal relationship with this treatment.
Time frame: First dose date up to the last dose date plus 30 days (maximum duration: 19 months)
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities
A treatment-emergent laboratory (Hematology, Serum Chemistry and Urinalysis) abnormality was defined as an abnormality that, compared to baseline, worsens by ≥ 1 grade in the period from the first dose of study drug. Safety as assessed by grading of laboratory values and AEs according to the National Cancer Institutes' Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Grade 0 = none, Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening or disabling. If baseline data are missing, then any graded abnormality (i.e., an abnormality that is Grade ≥ 1 in severity) will be considered treatment-emergent. The percentage of participants in each worst postbaseline grade is reported.
Time frame: First dose date up to the last dose date plus 30 days (maximum: 18 months)
Maximum Tolerated Dose Level
Maximum tolerated dose (MTD) is defined as the highest dose level that was consistently well tolerated without dose limiting toxicity (DLT) for the majority of participants time on treatment (ie,\> 50%) as determined by the investigator for each participant. DLTs are defined as Grade 4 hematological toxicities persisting for ≥ 14 days or Grade ≥ 3 toxicities of other types.
Time frame: First dose (entospelinib + idelalisib) date up to 6 months
Progression-free Survival (PFS)
PFS was defined as the interval from the first dose of study drug to the earlier of the first documentation of definitive disease progression or death from any cause.
Time frame: Start of treatment to end of treatment (Up to 18 months)
Duration of Response (DOR)
DOR was defined as the interval from the first-time response (CR or PR \[or VGPR or MR for participants with LPL/WM\]) is achieved to the earlier of the first documentation of definitive disease progression or death from any cause.CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined as a ≥ 50% reduction in the sum of the products of the longest perpendicular diameters of all index lesions, with no new lesions. VGPR and MR were defined as ≥ 90% and ≥ 25% but \< 50% decrease from baseline in serum monoclonal IgM concentration by SPEP respectively.
Time frame: Start of treatment to end of treatment (Up to 18 months)
Time to Response (TTR)
TTR was defined as the interval from the first dose of entospletinib/idelalisib to the time response (CR or PR \[or VGPR or MR for participants with LPL/WM\]) is first achieved. CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined as a ≥ 50% reduction in the sum of the products of the longest perpendicular diameters of all index lesions, with no new lesions. VGPR and MR were defined as ≥ 90% and ≥ 25% but \< 50% decrease from baseline in serum monoclonal IgM concentration by SPEP respectively.
Time frame: Start of treatment to end of treatment (Up to 18 months)
Participants were enrolled at study sites in the United States. The first participant was screened on 20 June 2013. The last study visit occurred on 22 December 2016.
| Milestone | Entospletinib + Idelalisib CLL | Entospletinib + Idelalisib iNHL: FL | Entospletinib + Idelalisib DLBCL | Entospletinib + Idelalisib MCL | Entospletinib + Idelalisib iNHL: Others |
|---|---|---|---|---|---|
| Started | 35 | 14 | 6 | 3 | 8 |
| Entospletinib monotherapy | 4 | 4 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 35 | 14 | 6 | 3 | 8 |
| Withdrew: Adverse event | 4 | 2 | 2 | 1 | 3 |
| Withdrew: Death | 2 | 0 | 0 | 0 | 1 |
| Withdrew: Initiated new therapy | 9 | 0 | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 5 | 4 | 1 | 0 | 1 |
| Withdrew: Progressive disease | 7 | 7 | 3 | 2 | 0 |
| Withdrew: Protocol criteria for withdrawal | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 0 | 0 | 0 | 1 |
ORR assessed by the Independent Review Committee (IRC), was based on the International Working Group Revised Response Criteria (Cheson, 2012) and investigator's response, defined as the percentage of participants achieving a complete response (CR) or partial response (PR) (or very good partial response \[VGPR\] or minor response \[MR\] for participants with LPL/WM). CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined as a ≥ 50% reduction in the sum of the products of the longest perpendicular diameters of all index lesions, with no new lesions. VGPR and MR were defined as ≥ 90% and ≥ 25% but \< 50% decrease from baseline in serum monoclonal immunoglobulin M (IgM) concentration by serum protein electrophoresis (SPEP) respectively.
No measurements were reported for this outcome.
A treatment-emergent Adverse Event (AE) was defined as any AE with an onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drugs or an AE leading to premature discontinuation of study drug. An AE is any untoward medical occurrence in a clinical investigation where participants administered a medicinal product, and which does not necessarily have a causal relationship with this treatment.
| percentage of participants | Entospletinib + Idelalisib CLL | Entospletinib + Idelalisib iNHL: FL | Entospletinib + Idelalisib DLBCL | Entospletinib + Idelalisib MCL | Entospletinib + Idelalisib iNHL: Others |
|---|---|---|---|---|---|
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events | 100 | 100 | 100 | 100 | 100 |
A treatment-emergent laboratory (Hematology, Serum Chemistry and Urinalysis) abnormality was defined as an abnormality that, compared to baseline, worsens by ≥ 1 grade in the period from the first dose of study drug. Safety as assessed by grading of laboratory values and AEs according to the National Cancer Institutes' Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Grade 0 = none, Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening or disabling. If baseline data are missing, then any graded abnormality (i.e., an abnormality that is Grade ≥ 1 in severity) will be considered treatment-emergent. The percentage of participants in each worst postbaseline grade is reported.
| percentage of participants | Entospletinib + Idelalisib CLL | Entospletinib + Idelalisib iNHL: FL | Entospletinib + Idelalisib DLBCL | Entospletinib + Idelalisib MCL | Entospletinib + Idelalisib iNHL: Others |
|---|---|---|---|---|---|
| Neutrophils Count Decreased (Grade 1) | 17.1 | 21.4 | 0 | 66.7 | 25.0 |
| Neutrophils Count Decreased (Grade 2) | 20.0 | 14.3 | 0 | 0 | 25.0 |
| Neutrophils Count Decreased (Grade 3) | 14.3 | 7.1 | 16.7 | 0 | 0 |
| Neutrophils Count Decreased (Grade 4) | 11.4 | 7.1 | 0 | 0 | 25.0 |
| Anemia (Grade 1) | 20.0 | 35.7 | 16.7 | 0 | 0 |
| Anemia (Grade 2) | 14.3 | 7.1 | 16.7 | 0 | 0 |
| Anemia (Grade 3) | 5.7 | 0 | 16.7 | 0 | 0 |
| Anemia (Grade 4) | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis (Grade 1) | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis (Grade 2) | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis (Grade 3) | 28.6 | 0 | 0 | 33.3 | 0 |
| Leukocytosis (Grade 4) | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Count Decreased (Grade 1) | 0 | 21.4 | 16.7 | 0 | 12.5 |
| WBC Count Decreased (Grade 2) | 14.3 | 0 | 16.7 | 33.3 | 12.5 |
| WBC Count Decreased (Grade 3) | 5.7 | 14.3 | 0 | 0 | 12.5 |
| WBC Count Decreased (Grade 4) | 0 | 0 | 0 | 0 | 12.5 |
| Lymphocyte Count Decreased (Grade 1) | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Decreased (Grade 2) | 0 | 0 | 16.7 | 33.3 | 12.5 |
| Lymphocyte Count Decreased (Grade 3) | 5.7 | 21.4 | 50.0 | 0 | 12.5 |
| Lymphocyte Count Decreased (Grade 4) | 0 | 0 | 0 | 33.3 | 0 |
| Lymphocyte Count Increased (Grade 1) | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte Count Increased (Grade 2) | 8.6 | 7.1 | 16.7 | 0 | 0 |
| Lymphocyte Count Increased (Grade 3) | 28.6 | 0 | 0 | 0 | 12.5 |
| Lymphocyte Count Increased (Grade 4) | 0 | 0 | 0 | 0 | 0 |
| Platelets Count Decreased (Grade 1) | 11.4 | 28.6 | 16.7 | 33.3 | 0 |
| Platelets Count Decreased (Grade 2) | 2.9 | 7.1 | 0 | 0 | 0 |
| Platelets Count Decreased (Grade 3) | 5.7 | 14.3 | 0 | 0 | 0 |
| Platelets Count Decreased (Grade 4) | 2.9 | 0 | 0 | 0 | 0 |
| Alanine Aminotransferase (ALT) Increased (Grade 1) | 22.9 | 7.1 | 33.3 | 0 | 50.0 |
| ALT Increased (Grade 2) | 8.6 | 7.1 | 0 | 0 | 0 |
| ALT Increased (Grade 3) | 0 | 35.7 | 16.7 | 33.3 | 0 |
| ALT Increased (Grade 4) | 5.7 | 0 | 0 | 0 | 12.5 |
| Hypoalbuminemia (Grade 1) | 14.3 | 28.6 | 0 | 0 | 12.5 |
| Hypoalbuminemia (Grade 2) | 5.7 | 0 | 16.7 | 33.3 | 0 |
| Hypoalbuminemia (Grade 3) | 0 | 0 | 16.7 | 0 | 0 |
| Hypoalbuminemia (Grade 4) | 0 | 0 | 0 | 0 | 0 |
| Alkaline Phosphatase (ALP) Increased (Grade 1) | 17.1 | 28.6 | 33.3 | 33.3 | 12.5 |
| ALP Increased (Grade 2) | 2.9 | 0 | 0 | 0 | 12.5 |
| ALP Increased (Grade 3) | 0 | 0 | 0 | 0 | 0 |
| ALP Increased (Grade 4) | 0 | 0 | 0 | 0 | 0 |
| Aspartate Aminotransferase (AST)Increased(Grade 1) | 20.0 | 14.3 | 50.0 | 0 | 37.5 |
| AST Increased (Grade 2) | 2.9 | 14.3 | 0 | 33.3 | 0 |
| AST Increased (Grade 3) | 0 | 28.6 | 16.7 | 0 | 12.5 |
| AST Increased (Grade 4) | 5.7 | 0 | 0 | 0 | 0 |
| Chronic Kidney Disease (Grade 1) | 34.3 | 42.9 | 50.0 | 33.3 | 37.5 |
| Chronic Kidney Disease (Grade 2) | 0 | 7.1 | 33.3 | 0 | 0 |
| Chronic Kidney Disease (Grade 3) | 0 | 0 | 0 | 0 | 0 |
| Chronic Kidney Disease (Grade 4) | 0 | 0 | 0 | 0 | 0 |
| Hyperglycemia (Grade 1) | 11.4 | 7.1 | 0 | 0 | 12.5 |
| Hyperglycemia (Grade 2) | 5.7 | 7.1 | 0 | 0 | 0 |
| Hyperglycemia (Grade 3) | 11.4 | 0 | 0 | 0 | 0 |
| Hyperglycemia (Grade 4) | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia (Grade 1) | 0 | 14.3 | 0 | 33.3 | 25.0 |
| Hypoglycemia (Grade 2) | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia (Grade 3) | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia (Grade 4) | 0 | 0 | 0 | 0 | 0 |
| Hypophosphatemia (Grade 1) | 0 | 0 | 0 | 0 | 0 |
| Hypophosphatemia (Grade 2) | 2.9 | 7.1 | 0 | 0 | 0 |
| Hypophosphatemia (Grade 3) | 5.7 | 0 | 16.7 | 0 | 12.5 |
| Hypophosphatemia (Grade 4) | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia (Grade 1) | 20.0 | 7.1 | 33.3 | 0 | 0 |
| Hypokalemia (Grade 2) | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia (Grade 3) | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia (Grade 4) | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia (Grade 1) | 20.0 | 0 | 50.0 | 0 | 0 |
| Hyponatremia (Grade 2) | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia (Grade 3) | 5.7 | 0 | 0 | 0 | 25.0 |
| Hyponatremia (Grade 4) | 0 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased (Grade 1) | 17.1 | 14.3 | 50.0 | 0 | 12.5 |
| Blood Bilirubin Increased (Grade 2) | 25.7 | 14.3 | 16.7 | 0 | 0 |
| Blood Bilirubin Increased (Grade 3) | 2.9 | 0 | 0 | 0 | 0 |
| Blood Bilirubin Increased (Grade 4) | 0 | 0 | 0 | 0 | 0 |
| Proteinuria (Grade 1) | 22.9 | 7.1 | 0 | 0 | 12.5 |
| Proteinuria (Grade 2) | 2.9 | 14.3 | 0 | 0 | 0 |
| Proteinuria (Grade 3) | 0 | 0 | 0 | 0 | 0 |
| Proteinuria (Grade 4) | 0 | 0 | 0 | 0 | 0 |
Maximum tolerated dose (MTD) is defined as the highest dose level that was consistently well tolerated without dose limiting toxicity (DLT) for the majority of participants time on treatment (ie,\> 50%) as determined by the investigator for each participant. DLTs are defined as Grade 4 hematological toxicities persisting for ≥ 14 days or Grade ≥ 3 toxicities of other types.
No measurements were reported for this outcome.
PFS was defined as the interval from the first dose of study drug to the earlier of the first documentation of definitive disease progression or death from any cause.
No measurements were reported for this outcome.
DOR was defined as the interval from the first-time response (CR or PR \[or VGPR or MR for participants with LPL/WM\]) is achieved to the earlier of the first documentation of definitive disease progression or death from any cause.CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined as a ≥ 50% reduction in the sum of the products of the longest perpendicular diameters of all index lesions, with no new lesions. VGPR and MR were defined as ≥ 90% and ≥ 25% but \< 50% decrease from baseline in serum monoclonal IgM concentration by SPEP respectively.
No measurements were reported for this outcome.
TTR was defined as the interval from the first dose of entospletinib/idelalisib to the time response (CR or PR \[or VGPR or MR for participants with LPL/WM\]) is first achieved. CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined as a ≥ 50% reduction in the sum of the products of the longest perpendicular diameters of all index lesions, with no new lesions. VGPR and MR were defined as ≥ 90% and ≥ 25% but \< 50% decrease from baseline in serum monoclonal IgM concentration by SPEP respectively.
No measurements were reported for this outcome.
Collected over First dose date up to the last dose date plus 30 days (maximum duration: 19 months); All-Cause Mortality: Baseline to Last Follow-Up Visit (Up to 3.6 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Entospletinib + Idelalisib CLL | 3/35 (8.6%) | 24/35 (68.6%) | 34/35 (97.1%) |
| Entospletinib + Idelalisib iNHL: FL | 1/14 (7.1%) | 2/14 (14.3%) | 14/14 (100%) |
| Entospletinib + Idelalisib DLBCL | 2/6 (33.3%) | 4/6 (66.7%) | 6/6 (100%) |
| Entospletinib + Idelalisib MCL | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| Entospletinib + Idelalisib iNHL: Others | 2/8 (25%) | 5/8 (62.5%) | 8/8 (100%) |
| Event | Entospletinib + Idelalisib CLL | Entospletinib + Idelalisib iNHL: FL | Entospletinib + Idelalisib DLBCL | Entospletinib + Idelalisib MCL | Entospletinib + Idelalisib iNHL: Others |
|---|---|---|---|---|---|
| Lung infectionInfections and infestations | 1/35 | 1/14 | 0/6 | 1/3 | 1/8 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/35 | 0/14 | 0/6 | 1/3 | 0/8 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 8/35 | 0/14 | 2/6 | 0/3 | 1/8 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/35 | 0/14 | 0/6 | 0/3 | 2/8 |
| SepsisInfections and infestations | 1/35 | 0/14 | 0/6 | 0/3 | 2/8 |
| HydronephrosisRenal and urinary disorders | 0/35 | 0/14 | 1/6 | 0/3 | 0/8 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/35 | 0/14 | 1/6 | 0/3 | 0/8 |
| PneumoniaInfections and infestations | 5/35 | 0/14 | 0/6 | 0/3 | 0/8 |
| Abdominal painGastrointestinal disorders | 0/35 | 1/14 | 0/6 | 0/3 | 0/8 |
| Abdominal pain upperGastrointestinal disorders | 1/35 | 0/14 | 0/6 | 0/3 | 0/8 |
| Event | Entospletinib + Idelalisib CLL | Entospletinib + Idelalisib iNHL: FL | Entospletinib + Idelalisib DLBCL | Entospletinib + Idelalisib MCL | Entospletinib + Idelalisib iNHL: Others |
|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 10/35 | 5/14 | 5/6 | 1/3 | 1/8 |
| NauseaGastrointestinal disorders | 14/35 | 7/14 | 4/6 | 1/3 | 1/8 |
| FatigueGeneral disorders | 15/35 | 6/14 | 4/6 | 0/3 | 3/8 |
| Decreased appetiteMetabolism and nutrition disorders | 5/35 | 1/14 | 4/6 | 0/3 | 1/8 |
| HeadacheNervous system disorders | 9/35 | 4/14 | 1/6 | 2/3 | 1/8 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/35 | 2/14 | 1/6 | 2/3 | 1/8 |
| ChillsGeneral disorders | 7/35 | 1/14 | 3/6 | 0/3 | 1/8 |
| DiarrhoeaGastrointestinal disorders | 14/35 | 2/14 | 2/6 | 0/3 | 1/8 |
| AnaemiaBlood and lymphatic system disorders | 5/35 | 0/14 | 2/6 | 0/3 | 0/8 |
| ConstipationGastrointestinal disorders | 11/35 | 2/14 | 2/6 | 0/3 | 0/8 |
The Full Analysis Set comprised all participants who received ≥ 1 dose of study drug (entospletinib or idelalisib).
| Age, Continuous(years) | Entospletinib + Idelalisib CLL | Entospletinib + Idelalisib iNHL: FL | Entospletinib + Idelalisib DLBCL | Entospletinib + Idelalisib MCL | Entospletinib + Idelalisib iNHL: Others | Total |
|---|---|---|---|---|---|---|
| Mean | 68 ± 12.9 | 64 ± 13.4 | 69 ± 17.4 | 62 ± 10.8 | 69 ± 8.9 | 67 ± 12.7 |
| Sex: Female, Male(Participants) | Entospletinib + Idelalisib CLL | Entospletinib + Idelalisib iNHL: FL | Entospletinib + Idelalisib DLBCL | Entospletinib + Idelalisib MCL | Entospletinib + Idelalisib iNHL: Others | Total |
|---|---|---|---|---|---|---|
| Female | 15 | 6 | 4 | 1 | 5 | 31 |
| Male | 20 | 8 | 2 | 2 | 3 | 35 |
| Race/Ethnicity, Customized(Participants) | Entospletinib + Idelalisib CLL | Entospletinib + Idelalisib iNHL: FL | Entospletinib + Idelalisib DLBCL | Entospletinib + Idelalisib MCL | Entospletinib + Idelalisib iNHL: Others | Total |
|---|---|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 |
| Ethnicity — Not Hispanic or Latino | 35 | 12 | 6 | 3 | 8 | 64 |
| Ethnicity — Not Permitted | 0 | 2 | 0 | 0 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Entospletinib + Idelalisib CLL | Entospletinib + Idelalisib iNHL: FL | Entospletinib + Idelalisib DLBCL | Entospletinib + Idelalisib MCL | Entospletinib + Idelalisib iNHL: Others | Total |
|---|---|---|---|---|---|---|
| Race — White/Caucasian | 27 | 11 | 6 | 3 | 8 | 55 |
| Race — Black or African American | 5 | 1 | 0 | 0 | 0 | 6 |
| Race — Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 0 | 1 |
| Race — Asian | 2 | 0 | 0 | 0 | 0 | 2 |
| Race — Other | 0 | 1 | 0 | 0 | 0 | 1 |
| Race — Not Reported | 0 | 1 | 0 | 0 | 0 | 1 |
| Karnofsky Performance Status(Participants) | Entospletinib + Idelalisib CLL | Entospletinib + Idelalisib iNHL: FL | Entospletinib + Idelalisib DLBCL | Entospletinib + Idelalisib MCL | Entospletinib + Idelalisib iNHL: Others | Total |
|---|---|---|---|---|---|---|
| 40 | 1 | 0 | 0 | 0 | 0 | 1 |
| 50 | 1 | 0 | 0 | 0 | 0 | 1 |
| 60 | 2 | 0 | 0 | 1 | 0 | 3 |
| 70 | 2 | 1 | 1 | 0 | 0 | 4 |
| 80 | 9 | 7 | 2 | 1 | 5 | 24 |
| 90 | 14 | 4 | 3 | 1 | 3 | 25 |
| 100 | 6 | 2 | 0 | 0 | 0 | 8 |
Ran from Jun 2013 to primary completion in Jan 2015, 19 months.
Results were first posted in Jun 2020, 5 years 5 months after primary completion. A results delay was requested in Mar 2015.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Entospletinib · Idelalisib
Leukemia, Lymphocytic, Chronic, B-Cell →